Skip to content
akaturk Academic measurement

OpenAlex topic

Adrenal Hormones and Disorders

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 1,777 works 27 author topics

Works

1,777 works

  1. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown. METHODS: . All the patients were…

  2. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  3. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  4. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  5. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety…

  6. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.9%

    CONTEXT: The diagnostic value of tests for detecting hypothalamic-pituitary adrenal insufficiency (HPAI) is controversial. OBJECTIVE: Our objective was to compare standard-dose and low-dose corticotropin tests for diagnosing HPAI. DATA SOURCES: We searched the PubMed database from 1966-2006 for studies reporting diagn…

  7. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.5%

    BACKGROUND: Immunodysregulation polyendocrinopathy enteropathy x-linked (IPEX) syndrome is a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (I…

  8. OpenAlex top 10% OpenAlex 96.8%

    No abstract yet.

  9. YÖKSİS SJR Q2 JCR Q3 OpenAlex top 1% OpenAlex 99.6%

    INTRODUCTION: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. METHODS:…

  10. YÖKSİS SJR Q2 JCR Q3 OpenAlex top 1% OpenAlex 99.6%

    INTRODUCTION: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. METHODS:…

  11. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.8%

    BACKGROUND: Authors of recent meta-analyses have reported that prolonged glucocorticoid treatment is associated with significant improvements in patients with severe pneumonia or acute respiratory distress syndrome (ARDS) of multifactorial etiology. A prospective randomized trial limited to patients with sepsis-associ…

  12. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.9%

    CONTEXT: Primary adrenal insufficiency (PAI) is a life-threatening condition that is often due to monogenic causes in children. Although congenital adrenal hyperplasia occurs commonly, several other important molecular causes have been reported, often with overlapping clinical and biochemical features. The relative pr…

Academicians

27 academicians